This is why Ra Pharmaceuticals, Inc. (RARX) share price is gaining 3.6% today

Ra Pharmaceuticals, Inc. | April 09, 2019

This is why Ra Pharmaceuticals, Inc. (RARX) share price is gaining 3.6% today
Ra Pharmaceuticals, Inc. (NASDAQ:RARX) is 0.83 points higher today and the only thing that matters is where they go from here. You simply have to look deeper than the share price and explore the fundamentals and future growth potential. The stock value has climbed by nearly 3.6% to $23.86 from its previous close of $23.03. Does this growth mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 206704 contracts so far this session. RARX shares had a relatively better volume day versus average trading capacity of 439.42 thousand shares, but with a 40.3 million float and a 10.77% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for RARX stock indicates that the average analyst price target is $38 per share. This means the stock has a potential increase of 59.26% from where the RARX share price has been trading recently which is between $22.8 and $24. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $32. The shorts are running away from Ra Pharmaceuticals, Inc. (RARX) stock. The latest set of short interest data was released on 15 March 2019, and the numbers show a drop in short interest in RARX shares. While short interest still represents only 3.71% of RARX’s float, the number of shares shorted have fallen by -162143. The number of shares shorted fell to 1496865 shares, down from 1659008 shares during the preceding fortnight. With average daily trading volumes at 814625 shares, days to cover decreased to about 4.686702 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “Ra Pharmaceuticals Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Pivotal Phase 3 gMG Study” and dated April 09, 2019.

Spotlight

Genetic engineering has been boosted by the discovery and characterization of CRISPR-associated Cas9 RNA-guided endonuclease. This technology enables rapid genetic perturbation and manipulation, as well as genome-wide functional screening. With broad basic science and translational applications, this technology is driving innovative life science and medical research.

Related News

VigiLanz launches COVID Quick Start software that gives hospitals customizable real-time alerts and reports to manage viral outbreaks

Prnewswire | May 21, 2020

Hospitals can prepare for additional waves of COVID-19 and flu season in a matter of weeks, with no payments for six months. COVID Quick Start gives hospitals customizable real-time alerts and reports to manage viral outbreaks and exposures. COVID Quick Start uses VigiLanz's clinical surveillance platform to help hospitals adapt to the evolving conditions associated with respiratory viral illnesses. VigiLanz, a clinical surveillance company, today announced COVID Quick Start – a new solution that will enable hospitals to prepare for, prevent, and respond to the spread of COVID-19 and other respiratory viral illnesses. COVID Quick Start gives hospitals customizable real-time alerts and reports to manage viral outbreaks and exposures. Partnering with Datica for rapid deployment and supported by a team of VigiLanz's certified infection preventionists, the software is designed to alleviate the burden on hospital IT resources and clinical staff while increasing patient safety. The solution is available for free for the first six months, with flexible financing options thereafter. COVID Quick Start uses VigiLanz's clinical surveillance platform to help hospitals adapt to the evolving conditions associated with respiratory viral illnesses. The platform continuously pulls patient data from a variety of sources, including EHRs, and evaluates that data against rules that issue real-time alerts to clinical staff. The rules are designed to identify potential respiratory viral illnesses, ensuring early isolation and management of patients, and can also track disease clusters to identify local outbreaks and hospital acquisition. Our team recognized that VigiLanz's software and expertise could be tailored to address the unique issues presented by this pandemic and other potential respiratory viral illnesses, and that we could design a solution with a low barrier to entry, We've built COVID Quick Start as a solution that works both for hospitals with well-funded infection prevention programs, and those where resources may be more restricted. These organizations are facing a possible second wave of COVID-19 on top of the upcoming influenza season. Our Quick Start solution, which provides the basics of what hospitals need to monitor – such as exposures, early case identification, COVID-19 state and federal reporting requirements, and isolation – will help hospitals quickly prepare for what is coming. -Stacy Pur, Vice President of Product Development at VigiLanz Read More: COVID-19 BRINGS DIVISIONS ON HYDROXYCHLOROQUINE, REOPENING Recognizing the urgency for hospitals to have a solution like this in place, COVID Quick Start uses VigiLanz Connect, an API solution for hospital EHRs, powered by Datica, to deliver an even faster integration. This solution minimizes the burden on hospital IT resources and enables COVID Quick Start to begin improving patient safety as quickly as possible. Datica has deep expertise, with over 400 successful EHR integrations," said Dave Levin, MD, Chief Medical Officer at Datica. "We're proud to collaborate with VigiLanz as their EHR integration partner to quickly launch their COVID Quick Start product." COVID Quick Start provides an easy and low-risk entry to the full suite of VigiLanz's SaaS-based clinical surveillance solutions. VigiLanz helps health systems avoid or minimize harm, optimize clinical outcomes, and support preventive care by aggregating and monitoring disparate data in real time from across the EHR and other health system databases. VigiLanz was ranked No. 1 by KLAS Research this year across three categories – Antimicrobial Stewardship, Infection Control and Monitoring, and Pharmacy Surveillance. This is the third year in a row it has earned Category Leader designations from KLAS. About VigiLanz Founded in 2001, VigiLanz is a privately held, rapidly growing provider of SaaS-based clinical surveillance solutions. The firm is focused on aggregating disparate EHR transactional workflow and documentation data across health systems to identify real-time clinical issues that avoid or minimize harm, optimize clinical outcomes and support preventive care. VigiLanz supports a large and growing community of hospital CMOs, CMIOs, CIOs, quality and safety teams, infectious disease and control specialists, pharmacists, and other clinicians dedicated to real-time inpatient and outpatient care. About Datica Datica is the only managed service provider (MSP) that solves healthcare's biggest roadblocks–EHR integration and cloud compliance. Its integration solution enables data integration from any source, to any destination, in any format - without sacrificing PHI security. Datica's cloud compliance solution offers end-to-end managed services for digital innovators to scale rapidly in the cloud, while ensuring HIPAA compliance and HITRUST certification are in place. With over 400 live integrations and compliant cloud infrastructure for Fortune 500 companies, Datica's deep expertise gives you the confidence and infrastructure to scale quickly and securely. Read More: TOP U.S. HEALTH OFFICIALS SELF-QUARANTINE AFTER COVID-19 CASES IN WHITE HOUSE

Read More

BUSINESS INSIGHTS

Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.

Glaukos | September 20, 2021

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc. under which Attillaps has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradication of Demodex mites, which are the root cause of Demodex blepharitis and often associated with meibomian gland dysfunction and related ophthalmic diseases. Demodex blepharitis and Demodex-driven meibomian gland dysfunction are caused by an infestation of Demodex mites, the most common ectoparasite found on human skin. Demodex blepharitis is characterized by eyelid inflammation and irritation resulting in eyelid redness, discomfort and debris. Demodex-driven meibomian gland dysfunction is characterized by decreased lipid secretion into the tear film and is a leading cause of dry eye disease. Under the agreement, Glaukos has the exclusive global right to research, develop, manufacture and commercialize products using certain acetylcholinesterase (AChE) inhibitors for the treatment of ophthalmic diseases caused by Demodex mites. Attillaps’ lead compounds have demonstrated promising in-vitro results in preclinical settings. We are incredibly excited about the development and commercial prospects of our novel platform in various therapeutic applications, particularly in the ophthalmology sector. Glaukos is a world-class ophthalmic company, and we couldn’t envision a more compelling licensing partner to advance our platform as a potential solution for the many patients suffering from these challenging conditions that currently have no approved treatments. - Frank Spallitta, founder and chief executive officer of Attillaps About Attillaps Attillaps is a developmental-stage pharmaceutical company pioneering novel drug platforms for the treatment of ophthalmology and dermatology conditions such as rosacea and blepharitis, with other indications of interest that include meibomian gland dysfunction, atopic dermatitis, acne vulgaris, ocular rosacea and hidradenitis suppurativa. The proprietary unique applications of these AChE inhibitors limit systemic exposure, further increasing the known safety of these molecules while effectively targeting the cutaneous inflammation. About Glaukos Glaukos is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in 2012, its next-generation iStent inject® device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos’ proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

Read More

PHARMA TECH

IDC: Pharmaceutical industry ups inventory levels as OTIF rates fall

Pharmaceutical | November 19, 2020

The decrease in OTIF can be credited to various issues all through the flexibly chain, as indicated by the report. Respondents noticed that diminished interest for non-COVID-19 medications and lost assembling limit were two of the most widely recognized interruptions. Walgreens Boots Alliance Global Chief Financial Officer James Kehoe noticed the drop sought after on an income call a month ago, saying the organization was encountering "lower interest for contents and administrations, reflecting diminished footfall." The greatest effect hosts been at the third-gathering coordinations level as transportation issues originating from tight limit swell across businesses, as per the IDC report. "Administering endpoints have seen the littlest effect, likely an element of high industry stock levels," the report peruses.

Read More

Spotlight

Genetic engineering has been boosted by the discovery and characterization of CRISPR-associated Cas9 RNA-guided endonuclease. This technology enables rapid genetic perturbation and manipulation, as well as genome-wide functional screening. With broad basic science and translational applications, this technology is driving innovative life science and medical research.